Merck & Co – known as MSD outside the US and Canada – and Moderna have announced positive phase 2b trial results investigating the use of their personalised mRNA cancer vaccine, mRNA-4157/V940, in ...

A group of scientists from the University of Surrey have shared findings from a seven-year research study, revealing that a new approach could be on the horizon for treating one of the most prevalent ...

BioNTech has announced it will acquire UK AI start-up InstaDeep in a deal worth up to £562m, following the company’s initial equity investment as part of InstaDeep’s Series B financing round in ...

Merck & Co is closing on a new indication for its checkpoint inhibitor Keytruda in early bladder cancer in the US, following a positive vote by an FDA expert panel. The Oncologic Drugs Advisory ...

AbbVie has bagged US approval for Skyrizi – a treatment for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The IL-23 inhibitor is expected to ...

This year, due to the COVID-19 pandemic and social distancing requirements, the PMEA Awards event will be streamed live at pmlive.com/pmea2020. After receiving a high ...

Merck – known as MSD outside the US and Canada – and Orna Therapeutics (Orna) have announced a collaboration agreement to advance Orna’s next generation of RNA technology. Under the terms of the ...

Johnson & Johnson’s (J&J) single-dose COVID-19 vaccine has scored a conditional marketing authorisation (CMA) from the European Commission, the company announced yesterday. J&J submitted its vaccine ...

World Hepatitis Day takes place today, with this year’s theme, ‘I can’t wait’, highlighting the need to accelerate the fight against viral hepatitis to reach the 2030 elimination target. The campaign, ...

The European Union is demanding that AstraZeneca (AZ) delivers 120 million doses of its COVID-19 vaccine by the end of June, threatening financial sanctions if the company fails to meet this target.

Five years ago, the revolution in remote working that has taken place would have been impossible to imagine. When 2020 hit, we had no choice but to change. The technology was in place, but there was ...

Merck KGaA and Pfizer have staked a claim to the first-line renal cell carcinoma market, with data on a new combination that analyst say could challenge to become a new standard for the disease. The ...